skip to Main Content

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI’s 15 member institutions

 Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael's Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

Minister of Economic Development, Employment and Infrastructure Brad Duguid announces the arrival of JLABS @ Toronto in the MaRS Discovery District. First row, left to right: Chris Halyk, president of Janssen Inc.; Melinda Richter, head of JLABS, Johnson & Johnson; Dr. Meric Gertler, president, University of Toronto; Minister Duguid; Dr. Ilse Treuricht, CEO MaRS Discovery District; Dr. Raphael (Rafi) Hofstein, president and CEO MaRS Innovation, and Robert Urban, head of Johnson & Johnson Innovation Boston. Second row: Dr. Robert Howard, president and CEO St. Michael’s Hospital; Dr. Catherine Zahn, president and CEO CAMH; Dr. Barry McLellan, president and CEO Sunnybrook Health Sciences Centre; Dr. Peter Pisters, president & CEO University Health Network; Dr. Jim Woddgett, director of research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and Dr. Michael Apkon, president and CEO, The Hospital for Sick Children.

 

TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto.

This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic Development Blog, BetaKit, Torontoist, and TechVibes.

It was also featured news on Rx&D‘s and Life Sciences Ontario‘s websites.

The new facility, called JLABS @ Toronto, will open in spring of 2016 at MaRS Discovery District and will support start-ups with lab space, programs, and potential investment partners as they work to build important, successful early-stage companies.

“The arrival of the Johnson & Johnson Innovation, JLABS model to MaRS’ West Tower reinforces Ontario’s position as one of the world’s leading life sciences clusters,” said Brad Duguid, Minister of Economic Development, Employment and Infrastructure. “JLABS @ Toronto will support researchers and entrepreneurs across the province and accelerate the development of Ontario companies while connecting Toronto to potential Johnson & Johnson collaborators and investors.”

“Research and innovation are fundamental to the mission of the University of Toronto,” said Dr. Meric S. Gertler, President, University of Toronto. “We host a vibrant entrepreneurial ecosystem featuring nine campus-led accelerators under the umbrella of our Banting & Best Centre for Innovation and Entrepreneurship. The addition of JLABS to this ecosystem will further propel the creation of new companies and new jobs, and ultimately new healthcare solutions that will benefit individuals and our society for years to come.”

“Toronto is home to a vibrant and prolific healthcare and life sciences community led by academic hospitals, world-class research institutions, top scientists, and a strong start-up ecosystem. For these reasons, Toronto is a natural choice for our first international expansion of JLABS,” said Melinda Richter, Head of JLABS. “The Johnson & Johnson Family of Companies has long been active within the Toronto Ontario community, forming many important collaborations. Today we are pleased to begin an even deeper relationship with this important community. Our new location, within a University of Toronto site, close to our hospital collaborators, and neighbouring the financial centre of Canada, will deliver great opportunities and impact for emerging biomedical technology entrepreneurs.”

Continue Reading

MaRS Innovation featured in International Innovation magazine

International Innovation feature on MIMaRS Innovation and its member institutions are is profiled in International Innovation‘s July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI’s president and CEO, written by Rosemary Peters.

The article is posted on the publication’s website and viewable through a digital interface (pages 80 and 81).

Here’s an excerpt from Dr. Hofstein’s comments:

“Canada’s academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the U.K. While this remains a matter of debate, I do agree that we need to continually encourage additional sources of seed capital to join is so as to allow for accelerated advancement of early-stage technologies. Industry needs to become much more engaged in advancing early-stage (and promising!) technologies emerging from the academic sector, which are usually young and in significant attention, navigation, management expertise and seed capital provisions. These are areas of rising importance in Canada, as many innovations fall into the ‘valley of death’ due to a lack of proper funding, or they leave the country and flourish in the U.S. where funding is more abundant.

Continue Reading

Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium

Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies

From left to right: Dr. Rafi Hofstein, president and CEO of MaRS Innovation; Professor Ruth Ross, director of the Centre for Collaborative Drug Research at the University of Toronto; Guy Seabrook, vice president of Neuroscience Scientific Innovation at Johnson & Johnson Innovation, California; the Honourable Reza Moridi, Minister of Research &Innovation; and Chris Halyk, president of Janssen Inc.
From left to right: Dr. Rafi Hofstein, president and CEO of MaRS Innovation; Professor Ruth Ross, director of the Centre for Collaborative Drug Research at the University of Toronto; Guy Seabrook, vice president of Neuroscience Scientific Innovation at Johnson & Johnson Innovation, California; the Honourable Reza Moridi, Minister of Research &Innovation; and Chris Halyk, president of Janssen Inc.

TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer’s disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million contribution to the Neuroscience Catalyst consortium, bringing the total raised for the open innovation fund to $3.7 million. Reza Moridi, Minister of Research and Innovation and Minister of Training Colleges and Universities, announced the contribution at the 2015 BIO International conference in Philadelphia during the opening of the Ontario pavilion.

This release was covered by Pharma TV and in TechVibes, BioSpace and Biotechnology Focus, and was referenced on the Canadian Science Policy Centre‘s and the Alzheimer Society of Toronto’s respective websites.

“We are pleased to support this collaborative innovation model which will accelerate the development of better treatment options for people with neurological disorders,” said Minister Moridi. “Partnerships between universities, academic hospitals, research institutes, industries and government are key to positioning Ontario as a global leader in Life Sciences.”

Founded by the University of Toronto (U of T) in partnership with Janssen Inc. and facilitated by Johnson & Johnson Innovation, the Neuroscience Catalyst consortium is using the Toronto research community’s well-established strengths in neuroscience to identify promising early-stage molecules and technologies through an open innovation model. The consortium aims to combine expertise to enable and accelerate the translation of basic sciences through to start-up companies and investor partnerships.

“We all want the next generation of solutions that are so desperately needed by patients and their families,” said Professor Ruth Ross, director of the Centre for Collaborative Drug Research at U of T. “In Canada, mood disorders such as depressive disorder and bipolar disorder affect about 10 per cent of the population. Alzheimer’s disease affects more than 745,000 Canadians. The need is urgent and this unique open collaborative partnership will allow us to rapidly develop new treatments.”

Other partners joining the project include MaRS Innovation, which introduced the partners to the Ministry of Research & Innovation and led the early conversation; Evotec, a global, high-quality provider in the drug discovery field; and Ontario Centres of Excellence (OCE), which is administering the funding.

Continue Reading
Back To Top